Following on from information provided to NICE by the company in April 2018, the appraisal of Plitidepsin with dexamethasone for treating multiple myeloma after 3 previous therapies including bortezomib and lenalidomide [ID1081] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1081 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in April 2018, the appraisal of Plitidepsin with dexamethasone for treating multiple myeloma after 3 previous therapies including bortezomib and lenalidomide [ID1081] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 20 April 2018 | Suspended. Following the referral of plitidepsin in combination with dexamethasone for treating relapsed or refractory multiple myeloma to NICE by the Department for Health and Social Care, the company have now confirmed that following a re-examination by the Committee for Medicinal Products for Human Use (CHMP), at the company’s request, a further refusal of the marketing authorisation was given on 22 March 2018. Therefore, the planned appraisal of plitidepsin in this indication has been suspended on the technology appraisals work programme. |
| 09 June 2017 | Following on from advice received from the company this appraisal has been rescheduled. Therefore, we now anticipate that the appraisal will begin during mid December 2017 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late February 2018. |
| 20 April 2017 - 19 May 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 05 December 2016 | Referral |
| 05 December 2016 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual